Jump to content

PAN Foundation

From Wikipedia, the free encyclopedia
Patient Access Network Foundation
Founded2004
TypeNon-profit
FocusPatients' out-of-pocket expenditure
Area served
United States
MethodDirect aid
Program funding
CEO
Kevin L. Hagan
Revenue
> US$451,000,000
Websitepanfoundation.org

The Patient Access Network Foundation (PAN Foundation) is a US-based non-profit 501(c)(3) organization that works to accelerate access to treatment through financial assistance, advocacy, and education. The organization was ranked #34 in Forbes' 2019 list of "top 100 US Charities", with private donations in 2019 totaling $434 million.[1] And in 2023, PAN was named to Fast Company's third annual Brands That Matter list, which recognizes companies and organizations of any size for their relevance, cultural impact, ingenuity, and business impact.[2]

Since 2004, the PAN Foundation reports it has given over $4.5 billion in financial assistance to over 1.2 million people, achieved major policy victories that increase access to care, mobilized thousands of patient advocates, and educated thoughts more on critical healthcare-related topics.[3]

Programs

[edit]

The PAN Foundation operates financial assistance, advocacy, and education initiatives to help accelerate access to care for those who need it most. Through its more than 80 disease-specific financial assistance programs, PAN serves well over 100,000 patients each year from every US state and territory.[4] Without the PAN Foundation’s support, these patients would have faced impossible choices—with many simply going without their life-saving treatment.

PAN advocates for change alongside its patient advocates and partners through policymaker outreach and education, research and polling within its Center for Patient Research, an annual Advocacy Action Summit that brings patients to connect with their elected officials on Capitol Hill, and campaigns and patient storytelling.[5] In addition, PAN leads educational initiatives that focus on topics that are often hard to explain and even more challenging for people to navigate—including recent Medicare Part D reforms, clinical trials, the federal Extra Help program, alternative funding programs, and copay accumulators.[6]  

In 2024, PAN launched a new Opening Doors to Clinical Trials national initiative aimed at creating a movement to increase diversity in clinical trials.[7]

Leadership

[edit]

In 2021, PAN appointed a new president and CEO, Kevin L. Hagan.[8][9] The PAN Foundation is governed by a Board of Directors, composed of experts and seasoned leaders from the healthcare, financial, legal and policy communities.[10]    

Controversy

[edit]

In 2019, PAN agreed to pay $4 million to settle allegations with the US Attorney's Office that they violated the False Claims Act by "enabling pharmaceutical companies to pay kickbacks to Medicare patients taking the companies’ drugs."[11]

References

[edit]
  1. ^ "Patient Access Network Foundation". Forbes. Retrieved 2021-10-06.
  2. ^ PAN, Foundation (2023-10-03). "PAN earns awards from Fast Company and Charity Navigator". PAN Foundation. Retrieved 2024-10-09.
  3. ^ "About us". PAN Foundation. Retrieved 2021-10-06.
  4. ^ "2023 Annual Report". PAN Foundation. Retrieved 2024-10-09.
  5. ^ "Our advocacy work". PAN Foundation. Retrieved 2024-10-09.
  6. ^ "Education initiatives". PAN Foundation. Retrieved 2024-10-09.
  7. ^ Werfhorst, Melissa Van De (2024-10-08). "Underrepresented groups are interested in clinical trials—but aren't being asked". PAN Foundation. Retrieved 2024-10-09.
  8. ^ "The PAN Foundation announces Kevin L. Hagan as next president and chief executive officer". PAN Foundation. 2021-09-13. Retrieved 2021-10-06.
  9. ^ "The PAN Foundation announces Kevin L. Hagan as next president and chief executive officer". www.yahoo.com. Retrieved 2021-10-06.
  10. ^ "Board of Directors". PAN Foundation. Retrieved 2024-10-09.
  11. ^ "Foundations Resolve Allegations of Enabling Pharmaceutical Companies to Pay Kickbacks to Medicare Patients". www.justice.gov. 2019-10-25. Retrieved 2021-10-06.